![]() |
市场调查报告书
商品编码
1792304
近距离放射治疗市场报告(按服务类型(病史和身体报告、出院总结、手术记录或报告、咨询报告等)、技术、采购模式、最终用户和地区划分),2025 年至 2033 年Brachytherapy Market Report by Service Type (History and Physical Report, Discharge Summary, Operative Note or Report, Consultation Report, and Others ), Technology, Mode of Procurement, End-User, and Region 2025-2033 |
2024 年全球近距离放射治疗市场规模达 8.881 亿美元。展望未来, IMARC Group预计到 2033 年市场规模将达到 12.159 亿美元,2025-2033 年期间的成长率 (CAGR) 为 3.55%。
近距离放射治疗,也称为体内放射治疗,是一种放射治疗形式,其放射线透过植入体内癌性肿瘤附近或旁边的放射源直接传输。此放射源产生的伽马射线聚焦于癌细胞,并减少对周围健康组织的损伤。近距离放射治疗依病情严重程度及其损伤程度,可采用低剂量率 (LDR) 或高剂量率 (HDR) 进行。 LDR 疗法将微小的放射性粒子永久植入肿瘤内或周围;而 HDR 疗法则在每次治疗结束时将放射源从患者体内移除,该疗法用于高风险癌症病例。
各类癌症发生率的上升是推动全球市场发展的关键因素之一。近距离放射治疗已被证明是治疗子宫颈癌、皮肤癌和乳癌极为有效的方法,这显着促进了该类市场的成长。此外,高品质的近距离放射治疗设备能够为小肿瘤提供精准且极其局部化的放射剂量,提高了患者和医务人员对该疗法的接受度。肿瘤治疗技术的进步和广泛的研发 (R&D),例如治疗新生血管性老年黄斑部病变的试验,也显着促进了市场的成长。此外,全球医疗旅游业的蓬勃发展,以及人们对近距离放射治疗的优势及其成本效益以及与手术或外照射治疗 (EBT) 相比更高的治癒率的认识不断提高,也显着推动了市场的发展。
IMARC 集团的最新报告深入洞察了全球近距离放射治疗市场,涵盖了其所有重要方面。报告涵盖了从宏观市场概览到微观产业表现、近期趋势、关键市场驱动因素和挑战、SWOT 分析、波特五力分析、价值链分析等内容。对于产业参与者、投资者、研究人员、顾问、商业策略家以及所有持有或计划以任何方式进军全球近距离放射治疗市场的人士而言,本报告都是必读之作。
The global brachytherapy market size reached USD 888.1 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,215.9 Million by 2033, exhibiting a growth rate (CAGR) of 3.55% during 2025-2033.
Brachytherapy, also known as internal radiation therapy, is a form of radiotherapy in which radiation is transported directly through a source implanted near or next to the cancerous tumor in the body. The source produces gamma rays that are focused on cancer cells and reduce the damage to surrounding healthy tissue. Brachytherapy is either administered in Low Dose Rate (LDR) or High Dose Rate (HDR) depending upon the severity of the disease and its damage. For LDR, small radioactive seeds are implanted permanently in or around the tumor, whereas, for HDR, radioactive sources are removed from the patient's body at the termination of each session and is used in the cases of high-risk cancers.
The rising prevalence of different types of cancer is one of the key factors driving the global market. Brachytherapy has been proven to be an extremely effective treatment option for cervical, skin and breast cancers, which is contributing significantly to its market growth. Furthermore, the availability of high-quality brachytherapy equipment that provides accurate and extremely localized doses of radiation to small tumors has enhanced the acceptance of the therapy amongst patients and medical professionals alike. Technological advancements in oncology treatments and extensive research and development (R&D), such as trials for treating neovascular age-related macular degeneration, have also provided a significant boost to the market growth. In addition to this, growing medical tourism across the globe, along with increasing awareness about the advantages of brachytherapy and its cost-effectiveness and increasing cure rate as compared to surgery or external beam therapy (EBT), is also significantly driving the market.
IMARC Group's latest report provides a deep insight into the global brachytherapy market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the global brachytherapy market in any manner.
The report has also analyzed the competitive landscape of the market with some of the key players being Acusis Software India Pvt Ltd., Transcend Services, Inc., Naunce Communications, Inc., MModal Global Services Pvt. Ltd., iMedX Information Services Pvt. Ltd., Global Medical Transcription LLC, nThrive Solutions LLC, MTBC (CareCloud, Inc.), Medi-Script Plus and Transtech Medical Solutions LLC.